Metrics as of 10/15/2026, 05:46 PM (Berlin time), refresh in progress.
Codexis Stock
Codexis, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Alison Moore
- Employees
- 146
- Market cap
- $136 M
- IPO
- 22/04/2010
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and…
Codexis stock: price history
1D
-8.8%
1W
-12.1%
1M
-7.5%
6M
-52.1%
YTD
-23.9%
1Y
-53.0%
2Y
-64.8%
5Y
-95.6%
10Y
-73.3%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~79% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Codexis
Analyst assessment of Codexis
PRICE TARGET LOW
US$5.00
CONSENSUS
US$8.00
MEDIAN
US$8.00
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
9
BUY
5
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 17/08/2026
Codexis stock metrics
P/E
-3.69
P/B
3.43
EV/EBITDA
-8.77
RETURN ON EQUITY
-36.4%
NET MARGIN
-80.5%
DEBT/EQUITY
2.2
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
75.2%
FLOAT SHARES
82,348,335
AVG. DAILY VOLUME (30D)
815,332
Insider transactions (SEC)
MOORE ALISON
Erbez Georgia
De Vre Raymond
Institutional holders
Comparable stocks
Frequently asked questions about Codexis stock
What does Codexis do?
Codexis, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Alison Moore, the company employs around 146 people.
The IPO was on 22/04/2010; the stock trades on NASDAQ under the ticker CDXS.
What do analysts say about Codexis stock?
14 analysts rate the stock, the consensus is Buy (as of 17/08/2026).
The average price target is US$8.00, ranging from US$5.00 to US$11.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does Codexis report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 79% stronger than usual.
Does Codexis pay a dividend?
No, Codexis currently does not pay a dividend.
Which stocks are comparable to Codexis?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Codexis stock analyzed?
Clicking "Analyze stock" lets five strategies assess Codexis against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.